Why bioAffinity’s CyPath Lung growth still leaves investors facing a hard cash question
CyPath Lung is gaining clinical traction. The harder test is whether bioAffinity can scale adoption before cash pressure tightens.
bioAffinity Technologies positions CyPath Lung as a confidence tool rather than a diagnostic replacement
Find out how bioAffinity Technologies’ CyPath Lung could reshape decision making for small lung nodules and what risks remain for adoption.